十一月 2025
- Home
- Teva Pharmaceuticals
十一月 2025的Teva Pharmaceuticals市场份额分析
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Teva Pharmaceuticals(包含公司地区分支机构)
查看更多网站流量和参与度信息- tevapharm.in
Teva Pharmaceuticals收入截至 十一月 2025为 > 1B
Teva Pharmaceuticals主要域名产生的收入
3 年中Teva Pharmaceuticals主要域名的收入
Teva Pharmaceuticals主要域名的收入
十一月 2025的Teva Pharmaceuticals股票价格
Teva Pharmaceuticals的股票交易代码为 TEVA。您可以在下面查看过去 12 个月的Teva Pharmaceuticals股票表现(最多 十一月 2025)
Teva Pharmaceuticals热门域名的总访问量
了解Teva Pharmaceuticals市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Teva Pharmaceuticals热门域名的平均访问时长
分析Teva Pharmaceuticals参与度指标。
过去 3 个月的平均访问时长
子公司明细
Teva Pharmaceuticals热门域名的平均页面浏览量
了解Teva Pharmaceuticals如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Teva Pharmaceuticals 采用的主要技术
这些是排名前 Teva Pharmaceuticals 的顶级域名所使用的网站技术(按行业分列)
准备好发现优质潜在客户了吗?
借助 Similarweb 销售情报解决方案,确定任意网站使用了哪些技术来设计完美的销售宣传,并缩短销售周期。
Teva Pharmaceuticals 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Takeda Pharmaceuticals partnered with Tevapharm on Jul 1st '20.For instance, in July 2020, Takeda Pharmaceutical Company Limited, a Japanese multinational pharmaceutical company, entered into a joint venture with Teva Pharmaceutical Industries Ltd., an Israeli multinational pharmaceutical company to focus on the commercialization of complex generics, specialty assets, and other pipeline opportunities.
五月 31, 2023阅读更多
新闻Tevapharm has issues with federal antitrust litigation over claims that it illegally pledged to stay out of the generic EpiPen market if two competing drugmakers delayed generic versions of the narcolepsy treatment Nuvigil.COMPANY INFO: Teva Pharmaceutical Industries Ltd. (Bloomberg Law Subscription) Teva Pharmaceutical Industries Ltd. is facing federal antitrust litigation over claims that it illegally pledged to stay out of the generic EpiPen market if two competing drugmakers delayed generic versions of the narcolepsy treatment Nuvigil.
十二月 5, 2022阅读更多
新闻Tevapharm sells assets to Marksans Pharma Limited.Marksans Pharma in a filing to exchanges said the company will acquire Teva Pharma’s business relating to the manufacture and supply of bulk pharmaceutical formulations in Plot No.
十月 13, 2022阅读更多
查看 Teva Pharmaceuticals 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。